Trials / Withdrawn
WithdrawnNCT02074020
CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Anthera Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the clinical efficacy of blisibimod as measured by a composite responder index in subjects who, despite corticosteroid use, continue to have autoantibody positive, clinically-active Systemic Lupus Erythematosus (SLE) as defined by SELENA SLEDAI score ≥10.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Blisibimod | Administered via subcutaneous injection once per week |
| DRUG | Placebo | Administered via subcutaneous injection once per week |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2018-06-01
- First posted
- 2014-02-28
- Last updated
- 2015-08-13
Source: ClinicalTrials.gov record NCT02074020. Inclusion in this directory is not an endorsement.